This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NW BIO AGAIN SETS FEUERSTEIN RECORD STRAIGHT

Stocks in this article: NWBO

BETHESDA, Md., April 7, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today again set the record straight:  Adam Feuerstein's latest, sensationalized headline claims about the Company's annual report and Phase III trial are once again factually wrong and materially misleading. 

Northwest Biotherapeutics Logo

This is the second time in a week that Feuerstein has falsely claimed that the Company itself stated negative information when, in fact, the Company did no such thing.  Accordingly, the Company advises all interested parties not to rely on any claims by Feuerstein about what the Company has said or done, and instead to investigate the information for themselves.

This time, Feuerstein materially misrepresents the Company's 10-K annual report with a dramatic headline claiming that "NW Bio Warns FDA May Throw Out Phase III Brain Cancer Study."  In fact, the Company's 10-K says no such thing and the Company has issued no such warning. 

Feuerstein also states that NW Bio "snuck a brand new risk nugget…into its annual report filed with the Securities and Exchange Commission on Tuesday."  This claim is also wrong.  In fact, the exact same risk factor language was included in the Prospectus filed last November which formed the basis for NW Bio raising $27 million from sophisticated institutional investors.

In attempting to support his false headline claim, Feuerstein points to and misrepresents the "Risk Factors" section of NW Bio's annual report.  As all experienced investors and analysts are well aware, the Risk Factors section of all companies' annual 10-Ks is meant to alert investors to the full range of worst-case scenarios, and describe all possible types of risks that could conceivably impact any aspects of a company's operations.  For any biotech company, there are typically dozens of risk factors or more.  Likewise, the Risk Factors section in NW Bio's 10-K annual report covering 2013 provides 14 pages of description of over 40 different risk factors relating to most aspects of the Company and its business.  Feuerstein points to a portion of one such risk factor and mischaracterizes it as some kind of new announcement by the Company.  It is not.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs